See the difference in the skin and joints

Primary endpoint of ACR20 at 12 weeks was achieved by 58% of patients treated with HUMIRA vs 14% with placebo (P<0.001)1
90% improvement (PASI 90) in skin lesions was achieved in 42% of HUMIRA-treated patients at Week 24 with response sustained through Week 481,4,5
70% improvement (ACR70) in joints was achieved in ~1 out of 4 HUMIRA-treated patients at Week 24 with response sustained through Week 481,4,5

* Improvement in degree and severity of skin lesions.

ADEPT was a 24-week, randomized, placebo-controlled trial (N=313) evaluating the safety and efficacy of adalimumab in patients with moderate-to-severe psoriatic arthritis who had an inadequate response to nonsteroidal anti-inflammatory drugs. The primary efficacy endpoints included ACR20 at Week 12 and mean change in modified Total Sharp Score at Week 24.1

All patients who completed the 24-week trial were eligible for long-term treatment with HUMIRA in an open-label extension (OLE) study. Patients in the placebo group switched to HUMIRA 40 mg every-other-week treatment from Week 24 to Week 48.1

06G-64C-Q352-7

HUMIRA is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. HUMIRA is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 4 years of age and older. HUMIRA can be used alone or in combination with methotrexate. HUMIRA is indicated for reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage and improving physical function in adult patients with psoriatic arthritis. HUMIRA is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis. HUMIRA is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn's disease who have had an inadequate response to conventional therapy, and reducing signs and symptoms and inducing clinical remission in these patients if they have also lost response to or are intolerant to infliximab. HUMIRA is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. HUMIRA should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician.

Please see Important Safety Information. Serious and sometimes fatal side effects have been reported with HUMIRA, including tuberculosis and other serious infections.

Please see full prescribing information.

References: 1. Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005;52:3279-3289. 2. Enbrel full prescribing information. 3. Remicade full prescribing information. 4. Gladman DD, Mease PJ, Ritchlin CT, et al. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum. 2007;56:476-488. 5. HUMIRA full prescribing information.

Legal Notices/Privacy Policy. Copyright 2007, Abbott Laboratories, Abbott Park, Illinois, U.S.A. If you have any questions about Abbott's HUMIRA.com Web site that have not been answered click here. This Web site and the information contained herein is intended for use by US residents only, is provided for informational purposes only and is not intended to replace a discussion with a healthcare provider. All decisions regarding patient care must be made with a healthcare provider and consider the unique characteristics of each patient.